• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/3/21 4:46:48 PM ET
    $CGIX
    Medical Specialities
    Health Care
    Get the next $CGIX alert in real time by email
    SC 13G 1 sc13g.htm

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No.   )*
     

     
    Cancer Genetics, Inc.
     
     
    (Name of Issuer)
     

     
    Common Stock, $0.0001 par value per share
     
     
    (Title of Class of Securities)
     

     
    13739U203
     
     
    (CUSIP Number)
     

     
    February 1, 2021
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    [ ]
    Rule 13d-1(b)
     
    [x]
    Rule 13d-1(c)
     
    [ ]
    Rule 13d-1(d)
     

     

    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)

    Lind Global Macro Fund, LP

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a) [ ]
     
    (b) [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
     
    710,656
    6 Shared Voting Power
     
    0
    7 Sole Dispositive Power
     
    710,656
    8 Shared Dispositive Power
     
    0
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    710,656(1)
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    9.9%(2)
    12
    Type of Reporting Person (See Instructions)

    PN
    (1) The reporting persons’ ownership consists of (a) 689,656 common shares and (b) warrants to purchase 689,656 common shares (the “Warrants”), however, due to the exercise limitations of the Warrants, the reporting persons’ beneficial ownership of the Warrants is currently limited to 21,000 Warrants.
    (2) Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 9.99% of the Company.

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)

    Lind Global Partners LLC

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a) [ ]
     
    (b) [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
     
    710,656
    6 Shared Voting Power
     
    0
    7 Sole Dispositive Power
     
    710,656
    8 Shared Dispositive Power
     
    0
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    710,656(1)
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    9.9%(2)
    12
    Type of Reporting Person (See Instructions)

    OO
    (1) The reporting persons’ ownership consists of (a) 689,656 common shares and (b) 689,656 Warrants, however, due to the exercise limitations of the Warrants, the reporting persons’ beneficial ownership of the Warrants is currently limited to 21,000 Warrants.
    (2) Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 9.99% of the Company.

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Jeff Easton

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a) [ ]
     
    (b) [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
     
    710,656
    6 Shared Voting Power
     
    0
    7 Sole Dispositive Power
     
    710,656
    8 Shared Dispositive Power
     
    0
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    710,656(1)
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    9.9%(2)
    12
    Type of Reporting Person (See Instructions)
     
    IN
     
    (1) The reporting persons’ ownership consists of (a) 689,656 common shares and (b) 689,656 Warrants, however, due to the exercise limitations of the Warrants, the reporting persons’ beneficial ownership of the Warrants is currently limited to 21,000 Warrants.
    (2) Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 9.99% of the Company.

    Item 1.
     
     
    (a)
    Name of Issuer
       
     
    Cancer Genetics, Inc.
     
     
    (b)
    Address of Issuer’s Principal Executive Offices
       
     
    201 Route 17 North, 2nd Floor
    Rutherford, NJ 07070

    Item 2.
     
     
    (a)
    Name of Person Filing
       
     
    This statement is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):
     
    • Lind Global Macro Fund LP, a Delaware limited partnership;
    • Lind Global Partners LLC, a Delaware limited liability company; and
    • Jeff Easton, an individual and a citizen of the United States of America.
     
    Lind Global Partners LLC, the general partner of Lind Global Macro Fund, LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Macro Fund, LP.
     
    Jeff Easton, the managing member of Lind Global Partners LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Macro Fund, LP.
     
     
    (b)
    Address of Principal Business Office or, if none, Residence
       
     
    The address of the principal business office for each of the Reporting Persons is:
     
    444 Madison Ave, Floor 41
    New York, NY 10022
     
     
    (c)
    Citizenship
       
     
    See Row 4 of cover page for each Reporting Person.
     
     
    (d)
    Title of Class of Securities
         
       
    Common stock, $0.0001 par value per share.
         
     
    (e)
    CUSIP Number
       
     
    13739U203

    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
     

    Not applicable.
     
    Item 4.
    Ownership
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
     
     
    (a)
    Amount Beneficially Owned
       
     
    See Row 9 of cover page for each Reporting Person.
     
     
    (b)
    Percent of Class
       
     
    See Row 11 of cover page for each Reporting Person.

     
    (c)
    Number of shares as to which such person has:
     
       
    (i)
    sole power to vote or to direct the vote
         

    See Row 5 of cover page for each Reporting Person.
     
       
    (ii)
    shared power to vote or to direct the vote
         
     
    See Row 6 of cover page for each Reporting Person.
     
       
    (iii)
    sole power to dispose or to direct the disposition of
         

    See Row 7 of cover page for each Reporting Person.
     
       
    (iv)
    shared power to dispose or to direct the disposition of
         
     
    See Row 8 of cover page for each Reporting Person.
     

     
    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
     

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person
     

    Not applicable.
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     

    Not applicable.
     
    Item 8.
    Identification and Classification of Members of the Group
     

    Not Applicable.
     
    Item 9.
    Notice of Dissolution of Group
     

    Not Applicable.
     
    Item 10.
    Certification
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Exhibits
    Exhibit
     
    99.1
    Joint Filing Agreement by and among the Reporting Persons.
     


    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    February 3, 2021
     
         
    LIND GLOBAL MACRO FUND, LP
       
    By:
     
    Lind Global Partners LLC
     
     
    its General Partner
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    LIND GLOBAL PARTNERS LLC
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    JEFF EASTON
     
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton


    Get the next $CGIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGIX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CGIX
    SEC Filings

    View All

    SEC Form 3 filed by Cancer Genetics, Inc.

    3 - Vyant Bio, Inc. (0001349929) (Issuer)

    4/1/21 7:03:48 PM ET
    $CGIX
    Medical Specialities
    Health Care

    SEC Form 10-K filed by Cancer Genetics, Inc.

    10-K - CANCER GENETICS, INC (0001349929) (Filer)

    3/31/21 6:01:06 AM ET
    $CGIX
    Medical Specialities
    Health Care

    SEC Form 8-K filed by Cancer Genetics, Inc.

    8-K - CANCER GENETICS, INC (0001349929) (Filer)

    3/25/21 9:17:14 AM ET
    $CGIX
    Medical Specialities
    Health Care

    $CGIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cancer Genetics and StemoniX Announce Merger Closing

    Cancer Genetics, Inc. Renamed to Vyant Bio, Inc. Vyant Bio, Inc. will begin trading on Nasdaq under the symbol VYNT CHERRY HILL, N.J., March 31, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company” or “CGI”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, and StemoniX, Inc. (“StemoniX”), a company empowering the discovery of new medicines through the convergence of novel human biology and software technologies, today announced their recently approved transaction has closed, and in connection with the merger, Cancer Genetics, Inc. was renamed Vyant Bio, Inc. (“Vyant Bio”) effective March 30, 2021. StemoniX will operate as a wholly-owned subsidiary of t

    3/31/21 6:30:00 AM ET
    $CGIX
    Medical Specialities
    Health Care

    Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniX

    Combined entity creates an innovative platform to de-risk and accelerate the discovery and development of preclinical and clinical pipelines with biopharma partners as well as the proprietary pipeline of the combined company RUTHERFORD, N.J., March 25, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced the results of its March 24, 2021 shareholder meeting to approve the upcoming merger with StemoniX, Inc. ("StemoniX"). At a Special Meeting of Stockholders, CGI’s stockholders, upon the unanimous recommendation of the board of directors of CGI: (a) voted in favor of the issuance of shares of Commo

    3/25/21 9:15:00 AM ET
    $CGIX
    Medical Specialities
    Health Care

    Cancer Genetics Announces Roland J. Carrillo, PhD as Vice President of Business Development

    RUTHERFORD, N.J., March 18, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today the appointment of Roland J. Carrillo, PhD as the Vice President of Business Development. Dr. Carrillo brings over a decade of experience with drug discovery and translational science with extensive knowledge of business development, marketing, and sales operations. His latest role was at Crown Bioscience, where he held positions as Senior Director for Sales Operations and Director of Business Development. He also led efforts in sales enablement, research service commercialization, and new business unit creation.

    3/18/21 8:30:00 AM ET
    $CGIX
    Medical Specialities
    Health Care

    $CGIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: John R Fletcher was granted 8,676 units of Common Stock

    4 - Vyant Bio, Inc. (0001349929) (Issuer)

    4/1/21 9:48:08 PM ET
    $CGIX
    Medical Specialities
    Health Care

    SEC Form 4 filed by Marcus Boehm

    4 - Vyant Bio, Inc. (0001349929) (Issuer)

    4/1/21 9:46:47 PM ET
    $CGIX
    Medical Specialities
    Health Care

    SEC Form 4 filed by Joanna Horobin

    4 - Vyant Bio, Inc. (0001349929) (Issuer)

    4/1/21 9:32:36 PM ET
    $CGIX
    Medical Specialities
    Health Care

    $CGIX
    Leadership Updates

    Live Leadership Updates

    View All

    Cancer Genetics Announces Roland J. Carrillo, PhD as Vice President of Business Development

    RUTHERFORD, N.J., March 18, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today the appointment of Roland J. Carrillo, PhD as the Vice President of Business Development. Dr. Carrillo brings over a decade of experience with drug discovery and translational science with extensive knowledge of business development, marketing, and sales operations. His latest role was at Crown Bioscience, where he held positions as Senior Director for Sales Operations and Director of Business Development. He also led efforts in sales enablement, research service commercialization, and new business unit creation.

    3/18/21 8:30:00 AM ET
    $CGIX
    Medical Specialities
    Health Care

    $CGIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed

    SC 13D - CANCER GENETICS, INC (0001349929) (Subject)

    2/25/21 3:05:43 PM ET
    $CGIX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - CANCER GENETICS, INC (0001349929) (Subject)

    2/10/21 9:43:25 PM ET
    $CGIX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - CANCER GENETICS, INC (0001349929) (Subject)

    2/10/21 9:26:44 PM ET
    $CGIX
    Medical Specialities
    Health Care